- Land: Schweiz
Nachricht vom 12.03.2019 | 12:00
EBD Group: BIO-Europe Spring(R) 2019 comes to Vienna in two weeks for 13th annual springtime biopharma conference
DGAP-News: EBD Group / Key word(s): Conference
BIO-Europe Spring 2019(R) comes to Vienna in two weeks for 13th annual springtime biopharma conference
Carlsbad, CA and Vienna, Austria - March 12, 2019: On March 25-27, the thirteenth annual BIO-Europe Spring(R) international partnering conference will convene in Vienna, Austria, at the Messe Wien Exhibition and Congress Center. The event is expected to draw over 2,500 pharma and biotech executives seeking valuable partnerships and investment, who will participate in a projected 15,000+ one-to-one meetings during the three-day conference.
There is still time to sign up and request meetings with your best-fit partners. Click here to register before online registration closes on March 22.
The event is produced by EBD Group and hosted by LISAvienna, a joint life science platform operated by the Vienna Business Agency and Austria Wirtschaftsservice on behalf of the Austrian Federal Ministry for Digital and Economic Affairs and the City of Vienna.
The opening keynote plenary discussion, "Time to turn the ship: Exploring underserved therapeutic areas," on Monday, March 25, will feature speakers Michael Crowley, Head of BD for Pharma Research and Early Development at Roche Pharma Partnering; Cartier Esham, EVP for Emerging Companies, Biotechnology Innovation Organization (BIO); David Rossow, Founding Partner, Strategic Investment Fund at the Bill & Melinda Gates Foundation; Jonathan Wang, Senior VP and Head of BD at Zai Lab; and moderator Amy Schulman, Partner at Polaris Partners.
Monday afternoon features Business Development, Spotlight and Therapeutics tracks covering investing, Asia-Pacific trends, NASH, cell and gene therapies, oncology partnering, and more.
On Tuesday, there are sessions on digital medicine and European biotech, a plenary highlighting "A day in the life of experienced dealmakers," as well as a Startup Spotlight event sponsored by Eli Lilly and Company offering expert advice on fostering innovation, valuation, attracting partners, maximizing resources, and funding strategies, with presentations by a series of innovative early-stage biotech companies.
The Labiotech Refresh event on Wednesday covers the outlook for European biotech; in addition, there are several panels on microbiome therapeutics.
Large and midsize pharma, biotech, and academic organizations will present their innovations and technologies, and the exhibit hall will feature nearly 100 top-notch companies. Besides the 15,000+ one-to-one partnering meetings expected, informal networking opportunities abound at the evening receptions both at the venue and out on the town at the historic Vienna City Hall, the Hofburg Palace, and the Old World-style Gösserhalle.
Vienna is a biotech hub known for its thriving life science community where most of the top 20 multinational companies in biotech, pharma and medical devices have a presence, taking advantage of Austria's ideal geographical location at the heart of Europe.
For more information about BIO-Europe Spring and to register to attend the event, visit the BIO-Europe Spring website.
# # #
Additional links and information:
Follow BIO-Europe Spring 2019 on Twitter @EBDGroup (hashtag: #BIOEuropeSpring) or LinkedIn
EBD Group: BIO-Europe Spring(R) 2019 comes to ...
BIO-Europe Spring(R) comes to Vienna for Europ ...
Copenhagen welcomed over 4,200 life science ex ...
EBD Group: BIO-Europe(R) 2018 to bring 4,000 l ...
EBD Group: Global life sciences to convene in ...
SBF AG: Die Zeichen für profitables Wachstum stehen auf Grün!
Die SBF AG agiert als Spezialist für Deckensysteme für Schienenfahrzeuge. Die Bahntechnikindustrie gilt als nachhaltiger Wachstumsbereich. Vor dem Hintergrund der starken Positionierung, des eingeschlagenen Wachstumskurses sowie der erwarteten verstärkten Investitionen in den Bahntechniksektor haben wir für die Aktie einen fairen Wert von 3,62 EUR ermittelt. Wir stufen den Titel aufgrund des großen Kurspotenzials mit „Kaufen“ ein.
Der AKTIONÄR News
22. März 16:55 Deutsche Telekom: Es tut sich was
News im Fokus
Fresenius Medical Care ernennt Dr. Frank Maddux zum Chief Medical Officer
20. März 2019, 13:04
20. März 2019
Original-Research: Hochdorf Holding AG (von Montega AG): Halten
22. März 2019